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The differential impact of risk factors on mortality in hemodial-
ysis and peritoneal dialysis.
Background. While the survival ramifications of dialysis
modality selection are still debated, it seems reasonable to pos-
tulate that outcome comparisons are not the same for all pa-
tients at all times. Trends in available data indicate the relative
risk of death with hemodialysis (HD) compared to peritoneal
dialysis (PD) varies by time on dialysis and the presence of
various risk factors. This study was undertaken to identify key
patient characteristics for which the risk of death differs by dial-
ysis modality.
Methods. Analyses utilized incidence data from 398,940
United States Medicare patients initiating dialysis between 1995
and 2000. Proportional hazards regression identified the pres-
ence of diabetes, age, and the presence of comorbidity as factors
that significantly interact with treatment modality. Stratifying by
these factors, proportional and nonproportional hazards mod-
els were used to estimate relative risks of death [RR (HD:PD)].
Results. Of the 398,940 patients studied, 11.6% used PD as
initial therapy, 45% had diabetes mellitus (DM), 51% were
65 years or older, and 55% had at least one comorbidity. Among
the 178,693 (45%) patients with no baseline comorbidity, ad-
justed mortality rates in nondiabetic (non-DM) patients were
significantly higher on HD than on PD [age 18–44: RR (95% CI)
= 1.24 (1.07, 1.44); age 45–64: RR = 1.13 (1.02, 1.25); age 65+:
RR = 1.13 (1.05, 1.21)]. Among diabetic (DM) patients with
no comorbidity, HD was associated with a higher risk of death
among younger patients [age 18–44: RR = 1.22(1.05, 1.42)] and
a lower risk of death among older patients [age 45–64: RR =
0.92 (0.85, 1.00); age 65+: RR = 0.86 (0.79, 0.93)]. Within the
group of 220,247 (55%) patients with baseline comorbidity, ad-
justed mortality rates were not different between HD and PD
among non-DM patients [age 18–44: RR = 1.19 (0.94, 1.50); age
45–64: RR = 1.01 (0.92, 1.11); age 65+: RR = 0.96 (0.91, 1.01)]
and younger DM patients [age 18–44: RR = 1.10 (0.92, 1.32)],
but were lower with HD among older DM patients with base-
line comorbidity [age 45–64: RR = 0.82 (0.77, 0.87); age 65+:
RR = 0.80 (0.76, 0.85)].
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Conclusion. Valid mortality comparisons between HD and
PD require patient stratification according to major risk factors
known to interact with treatment modality. Survival differences
between HD and PD are not constant, but vary substantially
according to the underlying cause of ESRD, age, and level of
baseline comorbidity. These results may help identify technical
advances that will improve outcomes of patients on dialysis.
Over the past decade, a number of large-scale cohort
studies have examined the impact of dialysis modality
on the survival of individuals with end-stage renal dis-
ease (ESRD) [1–15]. Results appear to vary by country
and, in some cases, even within a country. For example,
registry data from Canada [6] and Denmark [11] show
that patients treated with peritoneal dialysis (PD) have
a lower risk of death than those treated with hemodialy-
sis (HD). In contrast, results in the United States appear
to be mixed, with some studies showing more favorable
outcomes for patients on HD compared to PD [4, 12, 13],
others showing little or no difference between modali-
ties [7, 16], and still others showing better outcomes for
patients on PD [9, 15]. Discrepant results among some
of these studies can be attributed to methodologic dif-
ferences, such as the use of prevalent versus incident
patients [4, 7–9], proportional versus nonproportional
hazards models [5–7, 9], and the degree of case-mix ad-
justment [11–13, 15].
Despite these differences, some very important trends
have emerged from these studies. First, mortality rates
for PD and HD are not proportional over time [5, 6, 8–
14]. The risk of death for PD is generally lower during
the first year or two of dialysis. Thereafter, the risk of
death is either comparable between the two modalities or
higher in patients on PD. A second trend common to these
studies is the identification of significant interactions be-
tween various risk factors and treatment modality. For
example, it has been consistently demonstrated that the
relative risk of death between PD and HD varies by age
and by primary cause of ESRD (diabetes vs. nondiabetic
causes) [1, 2, 4, 6–9, 11–14, 16–18]. Recently, Ganesh et al
[12] and Stack et al [13] identified important interactions
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between comorbidity and dialysis modality that had not
been accounted for in previous studies. The inclusion of
such key interactions is necessary if an accurate assess-
ment of mortality differences between PD and HD is to
be made.
We hypothesize that in the United States, differential
trends in mortality between HD and PD exist for im-
portant segments of the ESRD population. We further
postulate that, consistent with previous studies, the key
segments are defined by age, cause of ESRD, and baseline
level of comorbidity. The purpose of this study was to ex-
amine these hypotheses using data from a large cohort of
United States Medicare patients. Our specific goals were
to identify key risk factors for which the risk of death dif-
fers by dialysis modality, and to adjust mortality compar-
isons between HD and PD by stratifying on these factors.
The results were then compared with findings from other




Data on 398,940 United States Medicare patients who
began dialysis between 1995 and 2000 were obtained from
the Centers for Medicare & Medicaid Services (CMS)
on Medical Evidence Form 2728. New incident patients
who survived the first 90 days of ESRD were included in
the analysis. Initial modality (HD vs. PD) was defined by
the 60-day rule of the United States Renal Data System
(USRDS), whereby treatment modality is designated as
HD or PD if the patient was on that modality for at least
60 days prior to and including day 90 of ESRD. In order
to reflect temporal changes in practice patterns, patients
were grouped into two incident cohort periods: 1995 to
1997 (N = 185,704, HD = 160,008, PD = 25,696) and 1998
to 2000 (N = 213,236, HD = 192,698, PD = 20,538).
The primary outcome variable was all-cause mortal-
ity. Patients were followed a maximum of three years
(through September 30, 2001), or until death or transplan-
tation. Baseline covariates were: cohort period (1995–
1997, 1998–2000), age (18–44, 45–64, ≥65), gender, race
(Asian, black, white, other), cause of ESRD [diabetes
(DM) vs. nondiabetic causes (non-DM)], the presence
of comorbid conditions, body mass index (BMI, kg/m2),
glomerular filtration rate (GFR, mL/min), serum albumin
(SA, g/dL), and hemoglobin (Hgb, g/dL). Comorbid con-
ditions included congestive heart failure (CHF), ischemic
heart disease/myocardioal infarction (MI) (i.e., coronary
artery disease, CAD), cardiac arrest/dysrhythmia, cere-
brovascular disease (CVD), peripheral vascular disease
(PVD), chronic obstructive pulmonary disease (COPD),
current smoking status, cancer, and the inability to am-
bulate/transfer. Baseline GFR was determined using the
formula from the Modification of Diet in Renal Disease
study, which is based on serum creatinine, age, gender,
and race [19].
Statistical analysis
Baseline characteristics of HD and PD patients were
compared using Pearson chi-square tests. Factors asso-
ciated with the likelihood of using PD or HD were
determined using multiple logistic regression with ad-
justments made for baseline demographics, comorbidity,
and laboratory values. To adjust for case-mix differences,
a modality-specific analysis was conducted to identify
key factors that may have a significant interaction with
the two treatment modalities. This was done by fitting a
proportional hazards model separately to HD and PD
patients using an intent-to-treat (ITT) approach, and ad-
justing for gender, age, race, cause of ESRD, comorbid-
ity, and baseline values of GFR, BMI, SA, and Hgb. This
initial analysis identified cause of ESRD (DM, non-DM),
age (18–44, 45–64, ≥65), and the presence of comorbidity
at baseline (none vs. 1 or more) as key factors that sig-
nificantly interact with treatment modality. Stratifying by
these factors, proportional and nonproportional hazards
models using interval Poisson regression were used to
compare case-mix adjusted mortality rates between HD
and PD at successive 6-month intervals [8, 20, 21]. Aver-
age or time-independent relative risks (RR) of death for
HD compared to PD patients were estimated using a pro-
portional hazards model, while time-dependent relative
risks and adjusted patient survival curves were estimated
with a nonproportional hazards model. Relative risks
and corresponding 95% confidence intervals (CI) were
adjusted for case-mix differences in cohorts, age, gen-
der, race, cause of ESRD, individual comorbidities, and
laboratory values. To maintain an overall 5% error rate
associated with performing multiple comparisons across
12 possible strata, Sidak’s procedure was used to com-
pute 95% simultaneous confidence intervals and corre-
sponding P values [22]. To avoid imputing missing values
and making unnecessary parametric assumptions (e.g.,
assuming age has a linear effect on the risk of death),
age, BMI, GFR, SA, and Hgb were analyzed as discrete
categorical variables using previously defined categories
[23]. Missing laboratory values were categorized as not
available (NA) within the various analyses, a strategy that
has been used successfully in previous studies to avoid
excluding patients with missing values [2, 23]. All analy-
ses were done using the SAS statistical software package
version 8.2 (SAS, Inc., Cary, NC, USA); in particular,
the GENMOD procedure was used for interval Poisson
regression.
The primary analysis was carried out using an ITT
approach in which death was assigned to a patient’s ini-
tial treatment modality regardless of a change in ther-
apy during the course of follow-up. An as-treated (AT)
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analysis was also performed in which survival times were
censored 60 days following a change in therapy. In this
case, any death that occurred within 60 days following
a therapy change was attributed to the initial treatment
modality. Model goodness-of-fit was assessed by an anal-
ysis of deviance in which quasi-likelihood ratio tests were
conducted comparing the measured deviance of a set of
reduced stratified models to the deviance of a set of full
stratified models [24]. Specifically, separate models were
fit to each of four subgroups formed by stratifying pa-
tients according to their cause of ESRD (DM, non-DM)
and their level of baseline comorbidity (none vs. one or
more). Each model was adjusted for the effects associated
with all other covariates studied (including individual co-
morbidities for those having one or more comorbid con-
ditions) as well as all two-way interactions between those
covariates and treatment modality. To evaluate overall
goodness-of-fit across the four strata, these full two-way
interaction models were compared to reduced models ob-
tained by excluding all two-way interactions except for
the age × modality interaction. Additionally, goodness-
of-fit tests were done to determine if the age by modal-
ity interaction could also be dropped from the final set
of models. To account for unexplained variation caused
by the exclusion of higher-order interactions (i.e., three-
way interactions and higher), the usual likelihood ratio
test statistic was divided by an estimate of overdisper-
sion computed from the full model. The resulting quasi-
likelihood ratio test, as described and implemented in
the SAS procedure GENMOD, allows a goodness-of-fit
comparison that takes into account any lack of fit asso-
ciated with three-way, four-way, and higher order inter-
action terms not included in the full two-way interaction
model. As a result of these goodness-of-fit tests, patients
were subsequently stratified by age, as well as by cause
of ESRD (DM vs. non-DM) and comorbidity. A main-
effects proportional hazards model was then used to esti-
mate and compare average relative risks (HD:PD) within
each of the 12 strata, while a main-effects nonpropor-
tional hazards model was used to estimate and compare
time-dependent relative risks (HD:PD).
RESULTS
Baseline characteristics
The baseline characteristics of the patient population
are summarized in Table 1. Patients selected to PD were
generally younger, more likely to be white, and less likely
to have comorbid illnesses compared to those on HD.
Patients on PD also were more likely to have diabetes, a
slightly higher baseline GFR, significantly higher SA and
Hgb values, and less likely to be underweight or obese.
These patient characteristics are consistent with those in
previous studies [12, 13, 23], and demonstrate the need to
adjust for case-mix differences when comparing mortality
rates between the two therapies.
Risk adjusted comparisons—Intent-to-treat analysis
Modality-specific estimates of RR associated with pa-
tient cohort, gender, age, race, cause of ESRD, the pres-
ence of comorbidity, and baseline values of GFR, BMI,
SA, and Hgb are summarized in Table 2. Also included
are chi-square tests that compare the differences (inter-
actions) in log relative risks between HD and PD. Based
on the magnitude of the chi-square tests, diabetes and
age stand out as two factors for which the RR of death
differs substantially by treatment modality. A third fac-
tor that indirectly stands out as constituting a significant
interaction with treatment modality is the presence of co-
morbid conditions. Specifically, except for cancer, the RR
of death associated with the presence of a comorbidity
was higher among PD patients regardless of the specific
comorbidity. In agreement with recent publications [12,
13], we found a significant interaction between treatment
modality and the presence of CAD and CHF. Significant
interactions were also present between modality and pe-
ripheral vascular disease, cardiac arrest/dysrhythmia, and
the inability to ambulate/transfer.
To compare modalities in the presence of the various
interactions, patients were stratified into 12 groups de-
fined by age (18–44, 45–64, ≥65), cause of ESRD (DM,
non-DM), and the presence or absence of comorbid con-
ditions at baseline (none vs. one or more). Stratifying
patients according to the presence of comorbid condi-
tions was done for two reasons. First, it provided a means
to account for the various interactions observed between
modality and comorbidity (Table 2). Second, it allowed
for comparison of mortality rates between HD and PD
in a large (45%) subgroup of patients with no reported
comorbidity at baseline (Table 1). This is an important
subgroup in that it avoids issues related to severity of
comorbidity, at least to the extent that comorbidity was
assessed in this study.
Table 3 presents the number of deaths and correspond-
ing crude death rates (DR) and unadjusted and adjusted
RR of death for each of the 12 strata defined above.
Among non-DM patients, use of HD was associated with
significantly higher mortality among patients having no
reported baseline comorbidity (27% of the population).
Specifically, the risk of death was 24% higher among HD
patients aged 18–44 [RR (HD:PD) = 1.24, P < 0.001)]
and 13% higher among HD patients aged 45 and older
[RR (HD:PD) = 1.13, P < 0.01]. Among non-DM pa-
tients with comorbid conditions at baseline (28% of the
population), there were no overall differences in the rel-
ative risk of death; time-averaged relative risks (HD:PD)
ranged from 0.96 to 1.19 (P = NS).
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Table 1. Patient characteristics and association with modality selection
Total HD PD
Factor category (398,940) (352,706) (46,234) P value Odds ratio
Gender
Female 46% 46% 46% 0.411 1.00ref
Male 54% 54% 54% 0.86a
Age years
18–44 14% 13% 23% <0.001 2.81a
45–64 35% 34% 41% 1.95a
≥65 51% 53% 36% 1.00ref
Race
White 54% 53% 65% <0.001 1.00ref
Black 30% 31% 21% 0.45a
Other/NA 3%/12% 3%/13% 3%/11% 0.81a/0.63a
Cause of ESRD
Non-DM 55% 56% 55% <0.001 1.00ref
DM 45% 44% 45% 1.14a
Comorbidity
Congestive heart failure 30% 31% 22% <0.001 0.75a
Coronary artery disease 25% 25% 21% <0.001 0.98NS
Cardiac arrest/dysrhythmia 6% 6% 5% <0.001 1.10a
Cerebrovascular disease 8% 9% 6% <0.001 0.84a
Peripheral vascular disease 14% 14% 11% <0.001 0.93a
COPD 6% 7% 4% <0.001 0.71a
Current smoker 5% 5% 5% <0.001 1.03NS
Cancer 5% 5% 3% <0.001 0.69a
Unable to ambulate/transfer 4% 4% 2% <0.001 0.53a
No comorbid conditions 45% 43% 56% <0.001 1.64a
GFR mL/min
<5.0 16% 16% 15% <0.001 0.75a
5.1–10.0 53% 53% 54% 0.95a
>10.0 22% 22% 20% 1.00ref
NA 9% 9% 11% 0.99NS
BMI kg/m2
Underweight (<18.5) 6% 6% 4% <0.001 0.68a
Normal (18.5–25.0) 38% 38% 37% 1.00ref
Overweight (25.1–30.0) 25% 25% 28% 1.13a
Obese (>30.0) 22% 22% 20% 0.88a
NA 9% 9% 11% 0.82a
Albumin g/dL
<3.1 28% 29% 19% <0.001 0.45a
3.1–3.4 17% 18% 15% 0.63a
>3.4 26% 25% 38% 1.00ref
NA 28% 28% 28% 0.65a
Hemoglobin g/dL
<11 70% 71% 62% <0.001 0.65a
11–12 11% 10% 14% 0.93a
>12 7% 6% 9% 1.00ref
NA 12% 12% 14% 0.73a
NS, not significant (P > 0.05).
aP < 0.001 compared to the reference group.
For DM patients, the risk of death varied significantly
by age. Among younger (age <45) DM patients with
no baseline comorbidity, HD was associated with a 22%
higher rate of mortality compared to PD [RR (HD:PD)
= 1.22, P < 0.001]. No difference in risk was seen among
the younger DM patients with baseline comorbidity [RR
(HD:PD) = 1.10, P = NS]. Among DM patients age 45
and older (40% of the population), PD was associated
with higher mortality regardless of the presence of co-
morbidity. Specifically, among DM patients with no base-
line comorbidity (15% of the population), the risk of
death was 8% lower among HD patients aged 45–64 [RR
(HD:PD) = 0.92, P < 0.05], and 14% lower among HD
patients aged 65 and older [RR (HD:PD) = 0.86, P <
0.001]. For those older DM patients with baseline comor-
bidity (25% of the population), the risk of death was 18%
lower among HD patients aged 45–64 [RR (HD:PD) =
0.82, P < 0.001], and 20% lower among HD patients aged
65 and older [RR (HD:PD) = 0.80, P < 0.001].
As in previous studies, the RR of death between HD
and PD in this study was not proportional over time.
Using nonproportional hazards Poisson regression, we
estimated adjusted time-dependent RRs over consecu-
tive 6-month intervals for each of the 12 strata shown
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Table 2. Modality-specific relative risks (RR) associated with various
factors
Chi-square test
Factor HD PD Log(RRHD) −
category RRa RRa Log(RRPD) P value
Cohort
1995–1997 1.00ref 1.00ref – –
1998–2000 1.00 0.94 14.805 <0.001
Gender
Female 1.00 1.00 – –
Male 0.97 0.97NS 0.132 0.411
Age
18–44 1.00ref 1.00ref – –
45–64 1.57 1.97 51.028 <0.0001
≥65 2.80 3.82 95.321 <0.0001
Race
White 1.00ref 1.00ref – –
Black 0.74 0.77 2.088 NS
Asian 0.61 0.53 6.723 <0.01
Other/NA 0.73 0.77 3.926 0.048
Cause of ESRD
Non-DM 1.00ref 1.00ref – –
DM 1.13 1.45 202.874 <0.0001
Comorbidity
Congestive heart failure 1.23 1.37 33.905 <0.0001
Coronary artery disease 1.07 1.23 48.778 <0.0001
Cardiac arrest/ 1.14 1.21 4.373 0.037
dysrhythmia
Cerebrovascular disease 1.16 1.21 2.423 NS
Peripheral vascular 1.10 1.16 5.434 0.020
disease
COPD 1.18 1.19 0.069 NS
Current smoker 1.05 1.11 2.480 NS
Cancer 1.42 1.18 22.095 <0.0001
Unable to ambulate/ 1.53 1.95 29.856 <0.0001
transfer
GFR mL/min
<5.0 0.66 0.70 2.852 NS
5.1–10.0 0.78 0.78 0.012 NS
>10.0 1.00ref 1.00ref – –
NA 0.96 1.24 17.137 <0.0001
BMI kg/m2
Underweight (<18.5) 1.32 1.32 0.004 NS
Normal (18.5–25.0) 1.00ref 1.00ref – –
Overweight (25.1–30.0) 0.82 0.87 9.932 <0.01
Obese (>30.0) 0.75 0.92 75.810 <0.0001
NA 0.92 0.89 0.293 NS
Albumin g/dL
<3.1 1.37 1.54 25.285 <0.0001
3.1–3.4 1.20 1.25 3.500 NS
>3.4 1.00ref 1.00ref – –
NA 1.23 1.23 0.082 NS
Hemoglobin g/dL
<11 0.99NS 1.00NS 0.144 NS
11–12 0.99NS 0.97NS 0.162 NS
>12 1.00ref 1.00ref – –
NA 1.03NS 0.93NS 4.043 0.044
aAll RRs are significantly different from 1.00 (P < 0.05) unless otherwise noted.
in Table 3. The results, shown in Figures 1 and 2, are
qualitatively consistent with the average RRs presented
in Table 3. However, these time-dependent RRs reflect
an important and consistent trend across various patient
subgroups. Specifically, the risk of death is initially higher
among HD patients, and then, depending on the sub-
group, either reaches a level comparable to that of PD
(non-DM patients, younger DM patients) or becomes
lower than that of PD (older DM patients). This trend
of nonproportional mortality rates is also reflected in
the corresponding population-averaged adjusted survival
curves shown in Figures 3 and 4. Among non-DM pa-
tients and younger DM patients, adjusted patient survival
is initially higher among PD patients, and the survival ad-
vantage is retained throughout the 3-year follow-up pe-
riod. Conversely, among the older DM patients, survival
is comparable between PD and HD through the first year
of dialysis, but because PD mortality rates exceed those
of HD after 6 to 12 months, long-term survival is better
among HD patients.
Model goodness-of-fit
Goodness-of-fit was evaluated across the four strata
formed by the presence or absence of comorbidity (none
vs. one or more) and cause of ESRD (non-DM, DM).
To evaluate the need to also stratify by age, goodness-
of-fit tests across the four strata were done by compar-
ing full two-way interaction models with reduced mod-
els obtained by excluding all two-way interactions except
for the age by modality interaction. Table 4 shows that
there was no significant lack of fit across the four strata
when the age by modality interaction was included (P
> 0.319). However, when the age by modality interac-
tion was excluded from the individual models, there was
a significant lack of fit (P < 0.05) in three of the four
strata. These results indicate the need to further strat-
ify by age when comparing treatment modalities. Once
patients were stratified by cause of ESRD (DM vs. non-
DM), age (18–44, 45–64, ≥65), and the presence of base-
line comorbidity, no other risk factors were found to sig-
nificantly interact with treatment modality.
As-treated analysis
The results for time-averaged RR in the AT analysis
are shown in Table 5. In general, although this analysis
was qualitatively similar to the ITT analysis, it yielded
higher RRs of death for HD versus PD, a result that is
consistent with other studies carried out in the United
States, Canada, and Europe [5, 6, 11–13]. Likewise, time-
dependent analyses also yielded RR profiles that were
consistently higher for patients on HD compared to PD
(data not shown). These higher RRs for HD may re-
flect the effects of informative censoring associated with
switching modalities, especially in light of the higher
rate of switching from PD to HD. However, given that
deaths occurring within 60 days following a switch were
attributed to the initial modality, it is unlikely that the
differences in RR could be due solely to informative cen-
soring. Conversely, in an ITT analysis there is a strong
possibility that the estimated RRs will be attenuated
due to the misclassification of patients by modality. The
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Table 3. Crude death rates (DR) per 100 patient years with unadjusted and adjusted relative risks (HD:PD) stratified by comorbidity, cause of
ESRD, and age
Patient stratum HD PD Relative risk (HD:PD)
Comorbid conditions Cause of ESRD Age Deaths DR Deaths DR %Pts Crude RR Adjusted RR(95% CI)
None Non-DM 18–44 3244 6.4 453 4.2 8% 1.52 1.24 (1.07, 1.44)a
45–64 5887 10.3 958 8.5 9% 1.21 1.13 (1.02, 1.25)b
≥65 18,216 28.2 1878 24.1 10% 1.17 1.13 (1.05, 1.21)a
DM 18–44 1960 12.3 468 10.2 3% 1.21 1.22 (1.05, 1.42)b
45–64 8275 14.5 1665 16.8 8% 0.86 0.92 (0.85, 1.00)c
≥65 12,564 27.5 1515 33.0 7% 0.83 0.86 (0.79, 0.93)a
One or more Non-DM 18–44 1623 10.4 174 7.8 2% 1.33 1.19 (0.94, 1.50)NS
45–64 8791 18.1 1027 16.5 7% 1.10 1.01 (0.92, 1.11)NS
≥65 42,343 38.7 3354 38.2 19% 1.01 0.96 (0.91, 1.01)NS
DM 18–44 1636 17.0 329 15.5 2% 1.10 1.10 (0.92, 1.32)NS
45–64 15,103 22.0 2502 27.8 11% 0.79 0.82 (0.77, 0.87)a
≥65 30,926 38.5 2994 48.2 14% 0.80 0.80 (0.76, 0.85)a
NS, not significant (P > 0.05).
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Cause of ESRD = DM
Age = 45−64
Months of follow-up
Fig. 1. Relative risk of death, RR(HD:PD), among patients with no reported comorbidity at baseline. RRs are adjusted for age, gender, race, and
cause of ESRD, and baseline values of GFR, albumin, hemoglobin, and BMI.
misclassification occurs over time because some patients
who switch and are receiving HD are classified as being
on PD, while others listed as being on HD are actually
being treated with PD [8].
DISCUSSION
In the present study, we showed that differences in mor-
tality rates between HD and PD vary across segments of
the ESRD population. Using a modality-specific risk as-
sessment, three key factors that influence the RR of death
between HD and PD were identified: cause of ESRD
(DM vs. non-DM), age (18–44, 45–64, ≥65), and base-
line level of comorbidity (none vs. one or more comorbid
conditions). When we accounted for these interactions
in a stratified analysis, we found that HD was associated
with an increased risk of death in the 30% of the ESRD
population comprised of non-DM and younger DM pa-
tients with no reported baseline comorbidity. Conversely,
we found that PD was associated with an increased risk
of death in the 40% of the population comprised of DM
patients aged 45 and older. There were no differences
in adjusted patient survival between the two modalities
in the remaining 30% of the population comprised of
non-DM patients and younger DM patients with baseline
comorbidity.
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Cause of ESRD = DM
Age = 45−64
Months of follow-up
Fig. 2. Relative risk of death, RR(HD:PD), among patients with one or more reported comorbid conditions at baseline. RRs are adjusted for age,
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Fig. 3. Adjusted patient survival among patients with no reported comorbidity at baseline. Survival curves (HD, solid line; PD, dashed line) are
adjusted for age, gender, race, and cause of ESRD, and baseline values of GFR, albumin, hemoglobin, and BMI.
These results are in partial agreement with results from
other countries. For example, registry data from Canada
(N = 14,483 incident patients) [6] and Denmark (N =
7011 incident patients) [11] indicate that patients receiv-
ing PD have an overall lower risk of death than those
receiving HD. However, in both registries, the lower risk
of death with PD was less pronounced for DM patients
compared to non-DM patients, and was significant for
DM patients only in an AT analysis. In an ITT analy-
sis, neither the Canadian nor the Danish registry showed
a significant difference in survival between PD and HD
among older DM patients [RR (PD:HD) = 1.04, P = NS
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Fig. 4. Adjusted patient survival among patients with one or more reported comorbid conditions at baseline. Survival curves (HD, solid line; PD,
dashed line) are adjusted for age, gender, race, cause of ESRD, individual comorbid conditions, and baseline values of GFR, albumin, hemoglobin,
and BMI.
Table 4. Model goodness-of-fit based on an analysis of deviance chi-square test with degrees of freedom, v 2(DF), and corresponding P value
Chi-square goodness-of-fit test
Age × modality included Age × modality excluded
Baseline comorbidity Cause of ESRD Chi-square test P value Chi-square test P value
None Non-DM v 2(18) = 14.83 0.674 v 2(2) = 6.09 0.047
DM v 2(18) = 18.61 0.416 v 2(2) = 10.83 0.004
One or more Non-DM v 2(28) = 30.96 0.319 v 2(2) = 3.75 0.153
DM v 2(27) = 24.74 0.589 v 2(2) = 7.79 0.020
Table 5. Average relative risks (HD:PD) by method of analysis
Patient stratum ITT analysis As-treated analysis
Adjusted RR (HD:PD) Adjusted RR (HD:PD)
Comorbid conditions Cause of ESRD Age (95% CI) (95% CI)
None Non-DM 18–44 1.24 (1.07, 1.44)a 1.55 (1.30, 1.84)a
45–64 1.13 (1.02, 1.25)b 1.23 (1.10, 1.38)a
≥65 1.13 (1.05, 1.21)a 1.18 (1.09, 1.28)a
DM 18–44 1.22 (1.05, 1.42)b 1.45 (1.21, 1.74)a
45–64 0.92 (0.85, 1.00)c 0.98 (0.89, 1.07)NS
65+ 0.86 (0.79, 0.93)a 0.86 (0.79, 0.94)a
One or more Non-DM 18–44 1.19 (0.94, 1.50)NS 1.34 (1.03, 1.76)c
45–64 1.01 (0.92, 1.11)NS 1.10 (0.98, 1.22)NS
≥65 0.96 (0.91, 1.01)NS 0.98 (0.93, 1.04)NS
DM 18–44 1.10 (0.92, 1.32)NS 1.35 (1.09, 1.68)b
45–64 0.82 (0.77, 0.87)a 0.84 (0.78, 0.91)a
≥65 0.80 (0.76, 0.85)a 0.82 (0.77, 0.87)a
NS, not significant (P > 0.05).
aP < 0.0001; bP < 0.001; cP < 0.05.
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in both cases]. Since the percentage of DM patients is
much lower in these countries than in the United States,
the overall lower risk of death favoring PD in these stud-
ies probably reflects the relatively lower risk of death
among the comparatively higher percentage of non-DM
patients.
While our results may appear to differ from those of
other studies of the United States Medicare population,
they are actually quite similar. In a study of 117,158 inci-
dent Medicare patients (1994–1996), Collins et al demon-
strated an increased risk of death with HD versus PD
among non-DM patients and younger DM patients, and
an increased risk of death with PD among older DM pa-
tients, especially older female diabetics [9]. Unlike past
studies of prevalent-based Medicare patients [4, 7], the
study by Collins et al was restricted to incident patients
and, therefore, not prone to a vintage effect associated
with prevalent-based analyses. Other strengths of their
study include the stratification of patients by age and di-
abetic status and the use of interval Poisson regression
to account for nonproportionality in mortality rates be-
tween HD and PD. With regards to the latter, Collins
et al found that patients treated with HD generally
had higher adjusted mortality rates during the first 6 to
12 months of dialysis compared to those treated with PD,
a finding that is consistent with both our results and those
from the Canadian registry [5, 6] and Danish registry [11].
A major limitation of the Collins study was that no ad-
justments were made for case-mix differences in comor-
bidity and/or baseline laboratory values. Recent studies
have attempted to address these shortcomings. In a study
of 112,077 incident Medicare patients (1995–1997), Xue
et al compared 1-year survival rates between HD and
PD with adjustment for baseline demographics, BMI,
and laboratory values [15]. Consistent with our find-
ings, these authors found that HD was associated with
a higher adjusted risk of death among non-DM patients
[RR (HD:PD) = 1.135, P < 0.0001] and a lower adjusted
risk of death among DM patients [RR (HD:PD) = 0.882,
P < 0.0001].
In two related studies, Ganesh et al [12] and Stack et al
[13] address the limitations of the Collins study by adjust-
ing for differences in baseline comorbidity and laboratory
values using a nonproportional Cox regression analysis.
Their analyses of 107,922 incident Medicare patients re-
vealed a significant interaction between treatment modal-
ity and CAD [12] or CHF [13] as a comorbidity. When
the authors accounted for these important interactions
in their respective analyses, they both found that HD was
associated with a lower adjusted risk of death in DM pa-
tients and in non-DM patients with CAD or CHF, a group
comprising approximately 60% of the ESRD population.
Of the remaining 40% of patients (non-DM patients with-
out CAD or CHF), there were no significant differences
in adjusted survival between HD and PD.
As in the Collins study, the Ganesh [12] and Stack [13]
studies accounted for the known interaction between di-
abetes and modality, and used a nonproportional haz-
ards model to estimate adjusted time-dependent relative
risks. A further strength of these two studies is that, in
addition to stratifying patients by comorbidity (CAD or
CHF) and diabetes, they also adjusted for further case-
mix differences in patient demographics (gender, race,
age), baseline comorbidity, and baseline values of GFR,
SA, hematocrit, and BMI. Unfortunately, these studies,
as well as the study by Xue et al, failed to account for
an age by modality interaction that has been shown to be
present in numerous other studies [1, 2, 4, 6, 7, 9, 14]. This
interaction, if ignored, can result in estimated RRs that
may be misleading. In particular, if the RR of death dif-
fers according to age (i.e., an age by modality interaction
exists), then a RR that is adjusted for age, but averaged
over the different age groups, can be strongly influenced
by the RR of a particular age group that has a dispropor-
tionately larger sample size. For example, in our study,
69% of deaths occurred in the 51% of patients age 65 and
older. Since this older population contributes the major-
ity of deaths, ignoring the age by modality interaction can
lead to an estimate of overall risk that is unduly influenced
by the RR of death in this group, a result known as Simp-
son’s paradox [25]. As shown in our study, when the anal-
ysis is stratified by age as well as comorbidity and cause
of ESRD, one finds an increased risk of death associated
with HD among non-DM patients and an increased risk
of death associated with PD among older DM patients.
These results are consistent with other studies that have
estimated an age by modality interaction [7, 9].
Interestingly, unlike Ganesh et al [12] and Stack et al
[13], we did not find PD to be consistently associated
with an increased risk of death among non-DM patients
with baseline comorbidity. Only among non-DM patients
aged 65 and older was there any evidence of a higher
risk of death associated with PD and only after 6 to 12
months (Fig. 2). Moreover, this later increase in risk as-
sociated with PD was offset by the 32% excess mortal-
ity associated with HD during the first 6 months [RR
(HD:PD) = 1.32, P < 0.0001], as evident in a comparison
of corresponding adjusted survival curves for HD and PD
[Fig. 4, time-averaged RR (HD:PD) = 0.96, P= 0.268].
Since we used the presence of any comorbidity as a strati-
fying variable rather than a specific comorbid condition, it
is possible that our degree of stratification was too broad
to provide a careful assessment of risks in the non-DM
population, despite adjustment for the presence of indi-
vidual comorbidities. To evaluate this possibility, we per-
formed a sensitivity analysis in which patients with one
or more comorbid conditions at baseline were further
stratified into those with and without CHF. Results of
that analysis (Table 6) show no significant differences in
the adjusted risk of death between HD and PD among
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Table 6. Average relative risks (HD:PD) by presence or absence of CHF
Patient stratum
CHF absent CHF present
Comorbid conditions Cause of ESRD Age RR (95% CI) RR (95% CI)
One or more Non-DM 18–44 1.20 (0.90, 1.61)NS 1.10 (0.74, 1.63)NS
45–64 1.10 (0.97, 1.25)NS 0.88 (0.76, 1.02)NS
≥65 0.99 (0.91, 1.06)NS 0.94 (0.87, 1.00)NS
DM 18–44 1.14 (0.89, 1.46)NS 1.04 (0.80, 1.35)NS
45–64 0.84 (0.76, 0.93)a 0.80 (0.73, 0.86)a
≥65 0.81 (0.74, 0.89)a 0.80 (0.74, 0.85)a
NS, not significant (P > 0.05).
aP < 0.0001.
non-DM patients regardless of whether they had CHF.
This result is consistent with the overall goodness-of-fit
tests (Table 4) in that no interactions were found to ex-
ist between treatment modality and any of the individual
comorbidities, including CHF after stratification by cause
of ESRD, age, and the presence of comorbidity. This find-
ing probably reflects the importance that comorbidity in
general plays in modifying the risk profile of patients on
dialysis. Indeed, we found remarkably good agreement
between crude RRs (Table 3) and the adjusted RRs, es-
pecially among diabetic patients.
A key feature of our study was the application of a
modality-specific risk assessment to identify factors of the
ESRD population that impact mortality associated with
HD and PD. Specifically, we found that non-DM patients
had a higher adjusted risk of death on HD compared to
PD, with the degree of risk dependent on the presence of
comorbidity at baseline. In contrast, among DM patients,
outcomes differed between HD and PD according to age,
with younger patients (age <45) generally having better
outcomes on PD and older patients (age ≥45) having
better outcomes on HD.
These results suggest several areas where technical im-
provements to both HD and PD may lead to better out-
comes for patients undergoing maintenance dialysis. For
example, given that PD is associated with higher mor-
tality in older DM patients, it is natural to ask whether
there are any modifiable features of PD that could lower
this risk, or whether such excess mortality may be due
to other confounding factors. To that end, Collins et al
observed that older (age ≥55) female DM patients on
PD were at an increased risk of death due to infection
compared to those on HD [9]. These findings parallel the
20% higher rate of peritonitis observed among DM ver-
sus non-DM patients on PD [26], and suggest that contin-
ued improvements in PD connectology may help lower
the risk of infection and, in turn, lower mortality due to
infection. However, a higher rate of mortality due to in-
fection among DM patients on PD may also reflect a de-
gree of negative selection bias associated with diabetes.
Winkelmayer et al recently showed that during the first
3 months of dialysis, 12% of patients who started on HD
switched to PD [27]. They also showed that patients who
switched from HD to PD were 50% more likely to have
diabetic nephropathy as their primary cause of ESRD
(adjusted hazards ratio = 1.49, P = 0.004), independent
of timing of referral. This higher rate of switching may be
due in part to a greater incidence of HD access complica-
tions in DM patients [28–31]. Any negative selection of
diabetics to PD because of problems such as poor venous
access or poor hemodynamic stability may be a signal of
emerging comorbidity that is not captured by the classi-
fication of patients to DM or any other conditions listed
in the CMS medical evidence form, and might explain in
part the higher mortality associated with PD in older DM
patients.
Of equal concern is the degree to which glucose-
containing PD solutions inhibit glycemic control in DM
patients and elevate levels of advanced glycation end
products (AGEs) [32–35]. Tighter glycemic control has
been associated with better outcomes, including survival,
in pre-ESRD and ESRD diabetics patients [36–38]. The
fact that younger DM patients on PD have equal or better
survival compared to HD may reflect their ability to bet-
ter metabolize and utilize daily glucose loads that range
from 100 to 300 grams per day. Likewise, accumulation of
AGEs in dialysis patients has been associated with accel-
erated atherosclerotic cardiovascular disease [39]. It re-
mains to be seen whether alternative non–glucose-based
solutions will help reduce morbidity and mortality, espe-
cially in older DM patients undergoing PD.
We found that HD was associated with a higher risk of
death compared to PD for non-DM patients and younger
DM patients, especially for those with no comorbidity.
The increased risk of death with HD was confined to
the first 6 to 12 months of follow-up, and was signifi-
cant even for those patients with baseline comorbidity
(Figs. 1 and 2). At 6 months, adjusted death rates for non-
DM and younger DM patients on HD were 1.32 to 1.91
times higher than for those on PD. Such excess early mor-
tality can have a significant impact on long-term patient
survival, as is evident in Figure 3. A survival advantage
for PD is maintained for these patients throughout the 3-
year follow-up period, despite death rates comparable to
HD after 1 year. The early increased risk of death associ-
ated with HD may be due in part to a better preservation
Vonesh et al: Impact of comorbidity and modality selection on mortality 2399
of residual renal function (RRF) with PD, a higher inci-
dence of late referral with HD, and/or early complications
associated with vascular access in HD.
Peritoneal dialysis has been shown to better preserve
RRF compared to HD [40, 41]. Further, PD patients with
diabetes are twice as likely to lose their RRF after 1 year
compared to those without diabetes (adjusted odds ra-
tio = 2.17, P= 0.01) [41]. These results could explain in
part why non-DM patients on HD have higher mortal-
ity during the first year of dialysis compared to those on
PD. However, it is unlikely that such large reductions in
mortality over such a short time period (as much as 48%
in the first 6 months) can be attributed solely to better
preservation of RRF with PD [9].
The impact of late referral on mortality is unclear.
Some studies have shown an association between late re-
ferral and an increased risk of death, while other studies
have shown no relationship [42–48]. In some studies, late
referral seems to have had an impact on mortality early
in therapy [43, 48]. Winkelmayer et al [48] showed that
late referral was associated with a 36% increase in mor-
tality compared to early referral, but the excess mortality
was restricted to the first 90 days of dialysis. Moreover,
there does not seem to be any overwhelming evidence
to suggest that patients who are referred late are more
likely to use HD than PD. For example, two recent stud-
ies showed that timing of referral was not a determinant
factor in the initial choice of modality [27, 49]. Since our
study was restricted to Medicare patients who survived
the first 90 days of treatment, any immediate direct effect
of late referral on mortality should be minimal for both
PD and HD patients.
A high incidence of sepsis and other access-related in-
fections early in treatment is a plausible explanation for
the high initial mortality associated with HD. Infectious
complications of HD vascular access continue to be one
of the leading causes of morbidity and mortality in the
United States [28–31, 50–55]. Although evidence suggests
a higher mortality in association with the use of catheters
versus fistulas or grafts [51–54], the use of permanent
catheters in the United States is increasing at a rate faster
than that for AV fistulas [55].
At least some of the excess mortality associated with
HD during the first 6 to 12 months of treatment is likely
caused by access-related infections. In a study of nearly
5000 incident patients, the RR of death following an
episode of hospital-managed septicemia was 38% higher
for patients treated with HD compared to PD [56]. When
restricted to deaths from septicemia, the adjusted RR for
HD patients was twice that for PD patients. Similarly, data
from the 2003 USRDS Annual Data Report shows that
adjusted first-year hospitalization rates for sepsis are up
to three times higher for patients on HD compared to PD,
and the risk of death in the 6 months following the first
septicemia event is nearly 7-fold greater than in patients
without sepsis [55]. The use of AV fistulas versus venous
catheters has been shown to reduce the risk of septicemia
[28, 56, 57] and death [51–54]. Since the risk of septicemia
associated with venous catheters is elevated during the
first 6 months of dialysis [56], and mortality and hospi-
talizations are also elevated during this time, a decrease
in the use of permanent catheters and an increase in the
use of AV fistulas may lead to a reduction in the first-year
mortality associated with HD. Improvements in catheter
design and implementation may also help reduce the in-
cidence of septicemia, and thereby, reduce mortality.
As with any observational study, there are inherent
limitations to the current study. For example, no adjust-
ments were made for factors that directly relate to dial-
ysis modality selection, such as length of time patients
were aware of kidney failure, timing of nephrology refer-
ral, the timing and type of modality options education,
and patient attitude to the management of their disease
process. Given the fundamental differences between PD
and HD with respect to lifestyle and patient attitude, such
factors may be important determinants of survival differ-
ences between the two modalities. Likewise, data were
not available in this study to adjust for various socioe-
conomic factors that may be associated with patient out-
comes. Such factors, for example, may explain the enor-
mous gap in utilization of PD in the United States (10%
PD vs. 90% HD) compared to countries such as Canada
and Denmark (25% PD vs. 75% HD) [55]. Consequently,
while there is some degree of synergism in outcome com-
parisons among various countries, care should be taken
not to generalize results from this United States Medicare
population to other countries.
CONCLUSION
We found that mortality risks between HD and PD
vary substantially in clinically relevant and easily iden-
tifiable segments of the United States Medicare ESRD
population. If confirmed, findings like this may help in
matching patients to therapies, and in selecting interven-
tions amenable to hypothesis testing in a more formal
randomized controlled trial setting.
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